Oncology CME Courses

Oncology CME Courses

Format: Online Streaming Video
Price: Free
Release Date: May 12, 2016
Expiration Date: May 12, 2018
Summary:

Acute lymphoblastic leukemia (ALL) is one of a group of malignancies caused by cytogenetic DNA mutations of developing hematopoietic stem cell precursors and mostly common to children with peak incidence at 2-5 years of age. Although approximately 80% of ALL cases present in children, they also occur in adults.  The symptoms of ALL are non-specific and similar to those of acute myelogenous leukemia (AML), which patients usually have 1-3 months of complaints.

By the end of the session the participant will be able to:

  • Summarize the most impactful findings presented at ASH 2015 relating to ALL and apply them to patient cases, taking into account any relevant barriers to care.
  • Additional objectives to be dictated by clinical content
Format: Online Streaming Video
Price: Free
Release Date: 9/29/2017
Expiration Date: 9/29/2018
Summary:

This activity is intended for pediatric oncology nurses, pediatric nurses, oncology nurses, nurse practitioners, nurse managers, infusion nurses, research nurses, physician assistants, and other health care providers who care for or have an interest in pediatric patients with high-risk neuroblastoma

Format: Interactive Online, Online Streaming Video, PDF
Price: Free
Release Date: November 02, 2017
Expiration Date: November 02, 2019
Summary:

Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus. Helping the clinician discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies – among others – based on the most up-to-date research merits continuing education programming in MM.

By the end of the session the participant will be able to:

  • Recall updates in the staging, prognosis, and diagnosis of MM.
  • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
  • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
  • Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.
Format: Interactive Online
Price: Free
Expiration Date: 6/14/18
Summary:

Speakers:

Matthew H. Kulke, MD, MMSc, Associate Professor of Medicine, Director of the Neuroendocrine and Carcinoid Tumor Program at Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School

David C. Metz, MBBCh, is Professor of Medicine at the Perelman School of Medicine (University of Pennsylvania)

Topic and Learning Objectives

  • To incorporate evidence-based practices into the management of carcinoid syndrome
  • Review the efficacy and safety of treatment programs for carcinoid syndrome
  • To summarize the causes of carcinoid syndrome
  • Review the differential diagnosis and appropriate workup for the presenting symptoms

This activity is intended for US-based medical oncologists, endocrinologists and gastroenterologists, as well as oncology physician assistants, nurse practitioners, and nurses involved in the diagnosis and management of carcinoid tumors and carcinoid syndrome. Considering the symptoms and potential complications involved in carcinoid syndrome, clinicians in cardiology, dermatology, pulmonary medicine, surgery, radiology (including interventional, diagnostic, and nuclear medicine), internal medicine and primary care may also benefit from education.

Format: Online Streaming Video
Price: Free
Release Date: Dec 4, 2017
Expiration Date: Dec 4, 2019
Summary:

By the end of the session the participant will be able to:

  • Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
  • Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
  • Describe emerging (investigational) therapies for metastatic melanoma
  • Describe the challenges and barriers to care associated with treating patients with metastatic melanoma
Format: Online Publication
Price: Free
Release Date: 9/19/2017
Expiration Date: 9/19/2019
Summary:

Learning Objectives:

  • Summarize the most impactful findings presented at ASCO 2017 relating to Metastatic Melanoma and apply them to patient cases, taking into account any relevant barriers to care.
  • Additional objectives to be dictated by clinical content
Format: Online Streaming Video, Interactive Online, Multiple Formats
Price: Free
Release Date: Nov 17, 2017
Expiration Date: Nov 17, 2019
Summary:

By the end of the session the participant will be able to:

  • Apply screening criteria to a patient receiving AI therapy or androgen deprivation therapy
  • Describe the criteria for initiation of pharmacotherapy in a patient receiving AI therapy or androgen deprivation therapy and apply them to a patient case
  • Identify present pharmacotherapeutic treatments for management of a patient receiving AI therapy or androgen deprivation therapy, and describe their mechanisms of action and place in therapy
  • Describe the challenges associated with treating patients receiving AI or androgen deprivation therapies, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents and apply the information in optimizing patient care in a patient case




Format: Online Streaming Video, Multiple Formats
Price: Free
Release Date: Nov 1, 2017
Expiration Date: April 20, 2018
Summary:

Includes Topics in

  • HR deficiencies and BRCA mutations
  • Recurrent ovarian cancer
  • Data on available and emerging PARP inhibitors
  • Personalizing treatment selection
  • Companion Diagnostics
Format: Online Streaming Video
Price: Free
Release Date: Dec 4, 2017
Expiration Date: Dec 4, 2019
Summary:

By the end of the session the participant will be able to:

  • Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
  • Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
  • Describe emerging (investigational) therapies for metastatic melanoma
  • Describe the challenges and barriers to care associated with treating patients with metastatic melanoma



Format: Interactive Online
Price: Free
Release Date: October 2017
Expiration Date: October 2018
Summary:

Earn CME with these new modules on lung cancer which include education on advances in lung cancer treatment, surgical and radiofrequency-ablative techniques, targeted therapies, and immunotherapies. Each takes less than 30 minutes to complete! Visit IO University to access this free education now! This activity is intended for clinicians practicing interventional oncology (IO) or those who are interested in learning more about IO. Available modules:

  • Lung Cancer Screening
  • Staging and Diagnosis of Lung Cancer
  • Image-Guided Thermal Ablation of Lung Cancer
  • Lung Cancer Pathology: From Atypical Adenomatous Hyperplasia to Adenocarcinoma
  • Standard of Care Treatment Algorithms (Chemotherapy/Immunotherapy)
  • The Role of Surgery for Non-Small Cell Lung Cancer
  • Conventional and Stereotactic Radiotherapy for Lung Cancer

Format: Online Streaming Video
Price: Free
Release Date: May 9, 2016
Expiration Date: May 9, 2018
Summary:

By the end of the session the participant will be able to:

  • Describe the impact of biomarker and mutation testing and their results for the management of patients with NSCLC and apply this knowledge to patient cases.
  • Describe the role and impact of the initial biopsy, including the relevance of its timing and factors affecting quality of results.
  • Distinguish between different NSCLC disease subtypes on the basis of histology, biomarker, and mutation status and use the information to optimize care in the setting of patient cases.
  • Discuss the ways that NSCLC has proved resistant to treatments in past and the mechanisms of action of targeted therapies, present and emerging
  • Determine how to incorporate the following components into a NSCLC treatment regimen in a manner that optimizes efficacy, safety, and tolerability: sequencing, dose reduction, and biomarker and mutation status testing


Share This